News & Updates
Showing Urology articles
Showing

Less is more when treating benign prostatic hyperplasia with thermal water vapour
Thermal water vapour therapy that consists of a single injection per prostate lobe for benign prostatic hyperplasia (BPH) is both effective and safe, yielding similar improvements in lower urinary tract symptoms and quality of life when compared with a traditional approach that employed variable number of injections by prostate volume, as shown in a study.

Lower urinary tract symptoms common among women with endometriosis
Women with endometriosis are more likely to develop various lower urinary tract symptoms, including difficulty passing urine, having to urinate again within minutes of urinating, or still feeling full after urination, a study has found.

Lifestyle interventions ward off mobility disability in prostate cancer patients on ADT
An exercise and dietary lifestyle intervention regimen leads to better mobility outcomes among prostate cancer patients undergoing androgen deprivation therapy (ADT) as compared with standard-of-care management, a recent study has found. Moreover, social cognitive outcome measures seem to be predictive of such mobility outcomes.

Risk stratification criteria show good prognostic value in CRPC, but not enough to guide treatment
The risk stratification criteria used in the CHAARTED and LATITUDE trials can accurately assess prognosis in patients with castration-resistant prostate cancer (CRPC), but are insufficient to differentiate between the therapeutic outcomes of androgen receptor pathway inhibitors (ARPI) and docetaxel, a new study has found.

PSA mRNA in circulating tumour cells a potential new biomarker for prostate cancer progression
Levels of prostate specific antigen (PSA) mRNA in circulating tumour cells can be used alongside serum PSA protein levels to refine the assessment of disease progression in patient with metastatic castration-resistant prostate cancer (mCRPC), a new study has found.

High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
In patients with clinically localized Gleason 9–10 prostate cancer, dose-escalated radiotherapy confers better biochemical disease-free survival and prostate cancer-specific mortality than conventional doses, a recent study has found.



